Recent 8-K filings for ANIK

• April 29, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 5.02item 9.01 ◈ Earnings Releases ×2◈ executive_change ×2

  Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign

  Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.

• February 26, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 5.02item 9.01

  Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1

  Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.

• January 8, 2026, 6:59 PM ET leadership materiality 0.70 neutral item 2.02item 5.02item 9.01

  Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair

  Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.

• November 5, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 8.01item 9.01

  Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data

  Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.

• July 30, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 7.01item 9.01

  Anika's Hyalofast Phase III misses co-primary endpoints; plans PMA filing by end of 2025

  Hyalofast missed pre-specified co-primary endpoints (percent change in KOOS Pain and IKDC function vs microfracture) on statistical significance.

• July 30, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints

  Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%

• June 24, 2025, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.07item 9.01

  Anika Therapeutics stockholders approve 475,000-share increase in incentive plan

  Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.

• May 9, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%

  Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.

• April 10, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

  Anika Therapeutics announces departure of COO Anne Nunes, eliminates position

  Anne Nunes departs as Chief Operations Officer effective April 25, 2025.

• March 12, 2025, 7:59 PM ET earnings materiality 0.72 neutral item 2.02item 9.01

  Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%

  Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).

• March 11, 2025, 7:59 PM ET M&A materiality 0.55 positive item 2.01item 7.01item 9.01

  Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management

  Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).

• October 31, 2024, 7:59 PM ET M&A materiality 0.70 positive item 2.01item 7.01item 9.01

  Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical

  Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.

• October 31, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture

  Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).

• August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System

  Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).

• July 11, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Anika Therapeutics stockholders elect directors and ratify auditor at 2024 annual meeting

  Elected Sheryl L. Conley, William R. Jellison, Stephen O. Richard as Class I directors (2027 term).

• May 28, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal

  Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.

• May 8, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance

  Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).

• May 8, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02item 9.01 ◈ executive_change ×2

  Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024

  Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.68 · Most common event earnings

5 positive 3 negative 10 neutral

source · ANIK on sec.gov